Summary

Eligibility
for people ages 18-120 (full criteria)
Location
at UCSD UCSF
Dates
study started
study ends around
Principal Investigator
by Sue Yom (ucsf)
Headshot of Sue Yom
Sue Yom

Description

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether radiation therapy is more effective with cisplatin or cetuximab in treating oropharyngeal cancer.

PURPOSE: This phase III trial is studying radiation therapy with cisplatin or cetuximab to see how well it works in treating patients with oropharyngeal cancer.

Official Title

Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer

Details

Keywords

Head and Neck Cancer, Precancerous Condition, stage III squamous cell carcinoma of the oropharynx, stage IV squamous cell carcinoma of the oropharynx, human papilloma virus infection, Precancerous Conditions, Cetuximab, cisplatin, IMRT, IMRT + Cisplatin, IMRT + Cetuximab

Eligibility

Locations

Lead Scientist at University of California Health

  • Sue Yom (ucsf)
    I am a radiation oncologist who specializes in the treatment of head and neck, lung, and skin cancers. I serve on national guidelines committees outlining the best practices for these cancers. I design clinical trials to improve treatment of these cancers. I give lectures and design courses to help others learn more about how to best treat these cancers.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Radiation Therapy Oncology Group
ID
NCT01302834
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 987 people participating
Last Updated